Review
doi: 10.4155/tde.12.136.
siRNA therapeutics in the treatment of diseases
Affiliations
- PMID: 23323780
- DOI: 10.4155/tde.12.136
Item in Clipboard
Review
siRNA therapeutics in the treatment of diseases
Ther Deliv.
2013 Jan.
Free article
Abstract
siRNAs are a class of dsRNAs, 21-23 nucleotides in length, which are able to silence their target genes through enzymatic cleavage of target mRNA. The sequence-specific gene-silencing by siRNA can be used as a new therapeutic approach for treatment of a variety of diseases that are incurable by conventional drugs. Many efforts have been made to overcome the problems related to delivery, stability, off-target gene silencing and immunostimulatory effects of siRNA. Different studies have carried out done to improve in vitro and in vivo delivery of naked or formulated siRNAs. In this review, different aspects of using siRNA as a new class of drugs will be discussed.
Similar articles
-
In vivo imaging of the systemic delivery of small interfering RNA.Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2012 Jul-Aug;4(4):428-37. doi: 10.1002/wnan.1158. Epub 2012 Jan 6. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2012. PMID: 22228711 Review.
-
Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.J Biotechnol. 2006 Jun 25;124(1):12-25. doi: 10.1016/j.jbiotec.2005.12.003. Epub 2006 Jan 18. J Biotechnol. 2006. PMID: 16413079 Review.
-
siRNA conjugate delivery systems.Bioconjug Chem. 2009 Jan;20(1):5-14. doi: 10.1021/bc800278e. Bioconjug Chem. 2009. PMID: 19053311 Review.
-
Barriers to successful delivery of short interfering RNA after systemic administration.Clin Exp Pharmacol Physiol. 2008 Nov;35(11):1371-6. doi: 10.1111/j.1440-1681.2008.04992.x. Epub 2008 Jun 18. Clin Exp Pharmacol Physiol. 2008. PMID: 18565190 Review.
-
The design, preparation, and evaluation of asymmetric small interfering RNA for specific gene silencing in mammalian cells.Methods Mol Biol. 2013;942:135-52. doi: 10.1007/978-1-62703-119-6_7. Methods Mol Biol. 2013. PMID: 23027049
Cited by
-
Separation and Characterization of Therapeutic Oligonucleotide Isomer Impurities by Cyclic Ion Mobility Mass Spectrometry.J Am Soc Mass Spectrom. 2024 Sep 4;35(9):2156-2164. doi: 10.1021/jasms.4c00197. Epub 2024 Jul 31. J Am Soc Mass Spectrom. 2024. PMID: 39082615 Free PMC article.
-
Enhanced Cancer Theranostics with Self-Assembled, Multilabeled siRNAs.ACS Omega. 2018 Oct 31;3(10):12975-12984. doi: 10.1021/acsomega.8b01999. Epub 2018 Oct 10. ACS Omega. 2018. PMID: 30411024 Free PMC article.
-
Silencing Myostatin Using Cholesterol-conjugated siRNAs Induces Muscle Growth.Mol Ther Nucleic Acids. 2016 Aug 2;5(8):e342. doi: 10.1038/mtna.2016.55. Mol Ther Nucleic Acids. 2016. PMID: 27483025 Free PMC article.
-
Active targeted drug delivery for microbes using nano-carriers.Curr Top Med Chem. 2015;15(15):1525-31. doi: 10.2174/1568026615666150414123157. Curr Top Med Chem. 2015. PMID: 25877093 Free PMC article. Review.
-
Immunomodulation therapy offers new molecular strategies to treat UTI.Nat Rev Urol. 2022 Jul;19(7):419-437. doi: 10.1038/s41585-022-00602-4. Epub 2022 Jun 22. Nat Rev Urol. 2022. PMID: 35732832 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
